Febuxostat for the management of hyperuricaemia in patients with gout: A nice single technology appraisal

PharmacoEconomics

Volumn 29, Issue 2, 2011, Pages 133-140

  Stevenson, Matt ^a   Pandor, Abdullah ^a  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; COLCHICINE; FEBUXOSTAT; URIC ACID;

ARTICLE; CLINICAL PRACTICE; CLINICAL TRIAL; CONSULTATION; COST EFFECTIVENESS ANALYSIS; DOUBLE BLIND PROCEDURE; DRUG CONTRAINDICATION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; GOUT; HUMAN; HYPERURICEMIA; INCIDENCE; MATHEMATICAL MODEL; METHODOLOGY; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; SELF EVALUATION; SINGLE BLIND PROCEDURE; TREATMENT OUTCOME; URIC ACID BLOOD LEVEL;

BIOMEDICAL TECHNOLOGY; CLINICAL TRIALS AS TOPIC; GOUT; GOUT SUPPRESSANTS; HUMANS; HYPERURICEMIA; THIAZOLES;

EID: 78751636549     PISSN: 11707690     EISSN: 11792027     Source Type: Journal    
DOI: 10.2165/11535770-000000000-00000     Document Type: Article

References (20)

1. National Institute for Health and Clinical Excellence. Guide to the single technology appraisal (STA) process. London: NICE, 2006 Sep [online]. Available from URL: http://www.nice.org.uk/nicemedia/pdf/STA-Process-Guide.pdf [Accessed 2010 Apr1]
2. Teng GG, Nair R, Saag KG. Pathophysiology, clinical presentation and treatment of gout. Drugs 2006; 66: 1547-63
3. Mikuls TR, Farrar JT, Bilker WB, et al. Gout epidemiology: results from the UK General Practice Research Database, 1990-1999. Ann Rheum Dis 2005; 64: 267-72
4. Annemans L, Spaepen E, GaskinM, et al. Gout in the UK and Germany: prevalence, comorbidities and management in general practice 2000-2005. Ann Rheum Dis 2008; 67 (7): 960-6
5. Falasca GF. Metabolic diseases: gout. Clin Dermatol 2006; 24: 498-508
6. Yamanaka H, Togashi R, Hakoda M, et al. Optimal range of serum urate concentrations to minimize risk of gouty attacks during anti-hyperuricemic treatment. Adv Exp Med Biol 1998; 431: 13-8
7. Shoji A, Yamanaka H, Kamatani N. A retrospective study of the relationship between serum urate level and recurrent attacks of gouty arthritis: evidence for reduction of recurrent gouty arthritis with antihyperuricemic therapy. Arthritis Rheum 2004; 51 (3): 321-5
8. Zhang W, Doherty M, Bardin T, et al. EULAR evidence based recommendations for gout: part II. Management: report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2006; 65: 1312-24 (Pubitemid 44620440)
9. Jordan KM, Cameron JS, Snaith M, et al., on behalf of the British Society for Rheumatology. British Society for Rheumatology and British Health Professionals in Rheumatology guideline for the management of gout. Rheumatology (Oxford) 2007; 46: 1372-4
10. National Institute for Health and Clinical Excellence. Health technology appraisal: febuxostat for the management of hyperuricaemia in patients with gout. Final scope. London: NICE, 2007 Aug [online]. Available from URL: http://www.nice.org.uk/nicemedia/live/11830/36209/36209.pdf [Accessed 2010 Apr 1]
11. National Institute for Health and Clinical Excellence. Guide to the methods of technology appraisals. London: NICE, 2008 Jun [online]. Available from URL: http://www.nice.org.uk/media/B52/A7/TAMethodsGuideUpdatedJune2008. pdf [Accessed 2010 Apr 1]
12. Ipsen UK. Febuxostat for the treatment of gout. Single technology appraisal submission to the National Institute for Health and Clinical Excellence. Final 15 January 2008 - revised 14May 2008. London: Ipsen, 2008 [online].Available from URL: http://www.nice.org.uk/nicemedia/live/11830/40731/ 40731.pdf [Accessed 2010 Apr 1]
13. Stevenson M, Pandor A. Febuxostat for the management of hyperuricaemia in patients with gout. Sheffield: University of Sheffield, 2008 Mar 31 [online]. Available from URL: http://www.nice.org.uk/nicemedia/live/11830/40721/40721. pdf [Accessed 2010 Apr 1]
14. Becker MA, Schumacher R, Wortmann RL, et al. Febuxostat compared with allopurinol in patients with hyperuricaemia and gout. N Engl J Med 2005; 353: 2450-61
15. Schumacher HR, Becker MA, Wortmann RL, et al. Febuxostat vs allopurinol and placebo in subjects with hyperuricaemia and gout: the 28-week APEX study [poster]. The Annual Scientific meeting of the American College of Rheumatology; 2005 Nov 16-17; San Diego (CA)
16. Borstad GC, Bryant LR, Abel MP, et al. Colchicine for prophylaxis of acute flares when initiating allopurinol for chronic gouty arthritis. J Rheumatol 2004; 31: 2429-32
17. National Institute for Health and Clinical Excellence. Hyperuricaemia - febuxostat: appraisal consultation document. London:NICE, 2010 Mar 30 [online]. Available from URL: http://www.nice.org.uk/guidance/index.jsp?action= article&o=40696 [Accessed 2010 Apr 1]
18. National Institute for Health and Clinical Excellence. Appeal hearing: febuxostat for the management of hyperuricaemia in patients with gout. London: NICE, 2008 Oct [online]. Available from URL: http://www.nice.org.uk/ nicemedia/live/11830/42724/42724.pdf [Accessed 2010 Apr 1]
19. Stevenson M. NICE single technology appraisal of febuxostat for the treatment of hyperuricaemia. London: NICE, 2008 May 12 [online]. Available from URL: http://www. nice.org.uk/nicemedia/live/11830/40722/40722.pdf [Accessed 2010 Apr 1]
20. National Institute for Health and Clinical Excellence. Final appraisal determination: febuxostat for the management of hyperuricaemia in people with gout. London: NICE, 2008 Aug [online]. Available from URL: http://www.nice.org. uk/nicemedia/live/11830/41648/41648.pdf. [Accessed 2010 Apr 1]